세계의 심부전 POC 및 LOC 기기 시장 규모, 점유율 및 산업 동향 분석 보고서 : 검사 유형별, 최종 용도별, 기술별, 지역별 전망 및 예측(2023-2030년)

The Global Heart Failure POC And LOC Devices Market size is expected to reach $252.9 million by 2030, rising at a market growth of 16.4% CAGR during the forecast period.

Laboratories are essential in establishing and maintaining quality control measures for POC and LOC devices. Consequently, the Laboratories segment captured $13,632.5 thousands revenue in the market in 2022. Laboratories utilize LOC devices for in-depth profiling of cardiac biomarkers, allowing for a more comprehensive understanding of a patient's cardiac status. This information is valuable for risk stratification, treatment planning, and ongoing monitoring. Standardization of procedures, calibration, and quality assurance processes are critical to providing the accuracy and reliability of results obtained from these devices. Some of the factors impacting the market are Continuous advancements in technology, Growing prevalence of heart failure and Lack of standardized procedures and regulatory frameworks.

Technological advancements have led to the developing more sensitive and specific biosensor technologies. This improvement in detection capabilities allows for the accurate measurement of cardiac biomarkers, facilitating early and precise diagnosis of heart failure. Advances in microfluidic technologies and miniaturized systems have enabled smaller, portable POC and LOC device designs. These compact devices are suitable for use in various healthcare settings, including clinics, ambulances, and remote locations, enhancing accessibility and convenience. According to WHO, Cardiovascular diseases (CVDs) are the leading reason of death globally, taking an estimated 17.9 million lives each year. As the prevalence of heart failure rises, there is a growing recognition of the importance of early diagnosis. Aging populations often experience a higher prevalence of heart failure. POC and LOC devices, designed for ease of use and quick results, are well-suited to address the diagnostic needs of elderly patients, promoting better management of heart failure in this demographic. Thus, the above-mentioned factors will drive the market growth.

The pandemic spurred a surge in the adoption of telehealth and remote monitoring solutions to reduce the risk of exposure to the virus in healthcare settings. Expedited approvals and streamlined regulatory processes had facilitated the introduction of new POC and LOC devices into the market. This regulatory responsiveness is expected to be had long-term implications, creating a more agile framework for approving innovative medical technologies. The heightened awareness of health risks and the importance of proactive healthcare management had led to increased patient engagement. Patients are more open to leveraging technology to monitor their health, creating a conducive environment for adopting POC and LOC devices for managing heart failure. Thus, the COVID-19 pandemic positively impacted the market.

However, the absence of standardized procedures can lead to variations in manufacturing processes and product quality. Inconsistent manufacturing practices may result in variability in the performance of POC and LOC devices, affecting their reliability and accuracy in diagnosing heart failure. Without standardized device design and communication protocol procedures, interoperability becomes a challenge. POC and LOC devices may face difficulties integrating seamlessly with existing healthcare systems, including electronic health records (EHRs) and laboratory information systems (LIS). The absence of clear regulatory frameworks creates uncertainty for manufacturers, clinicians, and end-users. Without well-defined regulatory pathways, it may be challenging for companies to navigate the approval process, leading to delays in bringing innovative POC and LOC devices. Due to the above factors, market growth will be hampered in the coming years.

Test Type Outlook

On the basis of test type, the market is segmented into proteomic testing, metabolomic testing and genomic testing. In 2022, the proteomic testing segment dominated the market with maximum revenue share. The investigation of cardiovascular events through the lenses of genomics, proteomics, and metabolomics has been spurred by technological developments in omics. As a result, novel biomarkers and assays that can predict the risk of a myocardial infarction before the onset of symptoms are identified. As an illustration, a blood test developed by scientists at SomaLogic Inc. in April 2022 can forecast an individual's imminent mortality from heart attack, stroke, failure, and these conditions.

End Use Outlook

By end use, the market is classified into clinics, hospitals, home, assisted living healthcare facilities, and laboratory. The home segment projected a prominent growth rate in the market in 2022. Individuals with rudimentary training can observe a few user-friendly, high-tech innovations. People can utilize these devices at home or anywhere and obtain instant results. The integration of user-friendly devices, such as Philips' Minicare I-20, designed for non-laboratory personnel, catalyzes the adoption of testing products in residential environments. Home self-testing facilitates prompt clinic visits and enhances ambulatory care, stimulating segment expansion.

Technology Outlook

Based on technology, the market is fragmented into microfluidics, array-based systems, and others. In 2022, the microfluidics segment held the highest revenue share in the market. The increasing nervousness regarding the mortality and morbidity rates associated with cardiovascular diseases (CVD) has stimulated the market for biosensing devices that are rapid, portable, and cost-effective to detect cardiovascular events. The adoption rate of microfluidic biosensors has increased recently due to their ability to integrate and miniaturize functional protocols utilized in central laboratories onto a portable chip. Additionally, it provides numerous advantages, including reduced reagent/sample consumption and a swift turnaround time.

Regional Outlook

Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region witnessed the largest revenue share in the market. The has experienced substantial organic revenue growth due to the significant participation of American companies. For example, Quidel Corporation and Ortho Clinical Diagnostics Holdings plc executed a business combination agreement in December 2021. Enhanced patient access is being extended to point-of-care diagnostics, immunohematology, immunoassay, molecular diagnostics, clinical chemistry, and donor screening products.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Siemens Healthineers AG (Siemens AG), Danaher Corporation, F. Hoffmann-La Roche Ltd., BioMerieux S.A., QuidelOrtho Corporation, Trinity Biotech Plc, Jant Pharmacal Corporation, Abaxis, Inc. (Zoetis Services LLC) and Werfen, S.A.

Scope of the Study

Market Segments covered in the Report:

By Test Type

• Proteomic Testing
• Metabolomic Testing
• Genomic Testing

By End Use

• Clinics
• Hospitals
• Laboratory
• Assisted Living Healthcare Facilities
• Home

By Technology

• Microfluidics
• Array-Based Systems
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• Abbott Laboratories
• Siemens Healthineers AG (Siemens AG)
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• BioMerieux S.A.
• QuidelOrtho Corporation
• Trinity Biotech Plc
• Jant Pharmacal Corporation
• Abaxis, Inc. (Zoetis Services LLC)
• Werfen, S.A.

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Heart Failure POC And LOC Devices Market, by Test Type
  • 1.4.2 Global Heart Failure POC And LOC Devices Market, by End Use
  • 1.4.3 Global Heart Failure POC And LOC Devices Market, by Technology
  • 1.4.4 Global Heart Failure POC And LOC Devices Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market at a Glance

• 2.1 Key Highlights

Chapter 3. Market Overview

• 3.1 Introduction
  • 3.1.1 Overview
    • 3.1.1.1 Market Composition and Scenario
• 3.2 Key Factors Impacting the Market
  • 3.2.1 Market Drivers
  • 3.2.2 Market Restraints
• 3.3 Porter's Five Forces Analysis

Chapter 4. Global Heart Failure POC And LOC Devices Market by Test Type

• 4.1 Global Proteomic Testing Market by Region
• 4.2 Global Metabolomic Testing Market by Region
• 4.3 Global Genomic Testing Market by Region

Chapter 5. Global Heart Failure POC And LOC Devices Market by End Use

• 5.1 Global Clinics Market by Region
• 5.2 Global Hospitals Market by Region
• 5.3 Global Laboratory Market by Region
• 5.4 Global Assisted Living Healthcare Facilities Market by Region
• 5.5 Global Home Market by Region

Chapter 6. Global Heart Failure POC And LOC Devices Market by Technology

• 6.1 Global Microfluidics Market by Region
• 6.2 Global Array-Based Systems Market by Region
• 6.3 Global Others Market by Region

Chapter 7. Global Heart Failure POC And LOC Devices Market by Region

• 7.1 North America Heart Failure POC And LOC Devices Market
  • 7.1.1 North America Heart Failure POC And LOC Devices Market by Test Type
    • 7.1.1.1 North America Proteomic Testing Market by Country
    • 7.1.1.2 North America Metabolomic Testing Market by Country
    • 7.1.1.3 North America Genomic Testing Market by Country
  • 7.1.2 North America Heart Failure POC And LOC Devices Market by End Use
    • 7.1.2.1 North America Clinics Market by Country
    • 7.1.2.2 North America Hospitals Market by Country
    • 7.1.2.3 North America Laboratory Market by Country
    • 7.1.2.4 North America Assisted Living Healthcare Facilities Market by Country
    • 7.1.2.5 North America Home Market by Country
  • 7.1.3 North America Heart Failure POC And LOC Devices Market by Technology
    • 7.1.3.1 North America Microfluidics Market by Country
    • 7.1.3.2 North America Array-Based Systems Market by Country
    • 7.1.3.3 North America Others Market by Country
  • 7.1.4 North America Heart Failure POC And LOC Devices Market by Country
    • 7.1.4.1 US Heart Failure POC And LOC Devices Market
      • 7.1.4.1.1 US Heart Failure POC And LOC Devices Market by Test Type
      • 7.1.4.1.2 US Heart Failure POC And LOC Devices Market by End Use
      • 7.1.4.1.3 US Heart Failure POC And LOC Devices Market by Technology
    • 7.1.4.2 Canada Heart Failure POC And LOC Devices Market
      • 7.1.4.2.1 Canada Heart Failure POC And LOC Devices Market by Test Type
      • 7.1.4.2.2 Canada Heart Failure POC And LOC Devices Market by End Use
      • 7.1.4.2.3 Canada Heart Failure POC And LOC Devices Market by Technology
    • 7.1.4.3 Mexico Heart Failure POC And LOC Devices Market
      • 7.1.4.3.1 Mexico Heart Failure POC And LOC Devices Market by Test Type
      • 7.1.4.3.2 Mexico Heart Failure POC And LOC Devices Market by End Use
      • 7.1.4.3.3 Mexico Heart Failure POC And LOC Devices Market by Technology
    • 7.1.4.4 Rest of North America Heart Failure POC And LOC Devices Market
      • 7.1.4.4.1 Rest of North America Heart Failure POC And LOC Devices Market by Test Type
      • 7.1.4.4.2 Rest of North America Heart Failure POC And LOC Devices Market by End Use
      • 7.1.4.4.3 Rest of North America Heart Failure POC And LOC Devices Market by Technology
• 7.2 Europe Heart Failure POC And LOC Devices Market
  • 7.2.1 Europe Heart Failure POC And LOC Devices Market by Test Type
    • 7.2.1.1 Europe Proteomic Testing Market by Country
    • 7.2.1.2 Europe Metabolomic Testing Market by Country
    • 7.2.1.3 Europe Genomic Testing Market by Country
  • 7.2.2 Europe Heart Failure POC And LOC Devices Market by End Use
    • 7.2.2.1 Europe Clinics Market by Country
    • 7.2.2.2 Europe Hospitals Market by Country
    • 7.2.2.3 Europe Laboratory Market by Country
    • 7.2.2.4 Europe Assisted Living Healthcare Facilities Market by Country
    • 7.2.2.5 Europe Home Market by Country
  • 7.2.3 Europe Heart Failure POC And LOC Devices Market by Technology
    • 7.2.3.1 Europe Microfluidics Market by Country
    • 7.2.3.2 Europe Array-Based Systems Market by Country
    • 7.2.3.3 Europe Others Market by Country
  • 7.2.4 Europe Heart Failure POC And LOC Devices Market by Country
    • 7.2.4.1 Germany Heart Failure POC And LOC Devices Market
      • 7.2.4.1.1 Germany Heart Failure POC And LOC Devices Market by Test Type
      • 7.2.4.1.2 Germany Heart Failure POC And LOC Devices Market by End Use
      • 7.2.4.1.3 Germany Heart Failure POC And LOC Devices Market by Technology
    • 7.2.4.2 UK Heart Failure POC And LOC Devices Market
      • 7.2.4.2.1 UK Heart Failure POC And LOC Devices Market by Test Type
      • 7.2.4.2.2 UK Heart Failure POC And LOC Devices Market by End Use
      • 7.2.4.2.3 UK Heart Failure POC And LOC Devices Market by Technology
    • 7.2.4.3 France Heart Failure POC And LOC Devices Market
      • 7.2.4.3.1 France Heart Failure POC And LOC Devices Market by Test Type
      • 7.2.4.3.2 France Heart Failure POC And LOC Devices Market by End Use
      • 7.2.4.3.3 France Heart Failure POC And LOC Devices Market by Technology
    • 7.2.4.4 Russia Heart Failure POC And LOC Devices Market
      • 7.2.4.4.1 Russia Heart Failure POC And LOC Devices Market by Test Type
      • 7.2.4.4.2 Russia Heart Failure POC And LOC Devices Market by End Use
      • 7.2.4.4.3 Russia Heart Failure POC And LOC Devices Market by Technology
    • 7.2.4.5 Spain Heart Failure POC And LOC Devices Market
      • 7.2.4.5.1 Spain Heart Failure POC And LOC Devices Market by Test Type
      • 7.2.4.5.2 Spain Heart Failure POC And LOC Devices Market by End Use
      • 7.2.4.5.3 Spain Heart Failure POC And LOC Devices Market by Technology
    • 7.2.4.6 Italy Heart Failure POC And LOC Devices Market
      • 7.2.4.6.1 Italy Heart Failure POC And LOC Devices Market by Test Type
      • 7.2.4.6.2 Italy Heart Failure POC And LOC Devices Market by End Use
      • 7.2.4.6.3 Italy Heart Failure POC And LOC Devices Market by Technology
    • 7.2.4.7 Rest of Europe Heart Failure POC And LOC Devices Market
      • 7.2.4.7.1 Rest of Europe Heart Failure POC And LOC Devices Market by Test Type
      • 7.2.4.7.2 Rest of Europe Heart Failure POC And LOC Devices Market by End Use
      • 7.2.4.7.3 Rest of Europe Heart Failure POC And LOC Devices Market by Technology
• 7.3 Asia Pacific Heart Failure POC And LOC Devices Market
  • 7.3.1 Asia Pacific Heart Failure POC And LOC Devices Market by Test Type
    • 7.3.1.1 Asia Pacific Proteomic Testing Market by Country
    • 7.3.1.2 Asia Pacific Metabolomic Testing Market by Country
    • 7.3.1.3 Asia Pacific Genomic Testing Market by Country
  • 7.3.2 Asia Pacific Heart Failure POC And LOC Devices Market by End Use
    • 7.3.2.1 Asia Pacific Clinics Market by Country
    • 7.3.2.2 Asia Pacific Hospitals Market by Country
    • 7.3.2.3 Asia Pacific Laboratory Market by Country
    • 7.3.2.4 Asia Pacific Assisted Living Healthcare Facilities Market by Country
    • 7.3.2.5 Asia Pacific Home Market by Country
  • 7.3.3 Asia Pacific Heart Failure POC And LOC Devices Market by Technology
    • 7.3.3.1 Asia Pacific Microfluidics Market by Country
    • 7.3.3.2 Asia Pacific Array-Based Systems Market by Country
    • 7.3.3.3 Asia Pacific Others Market by Country
  • 7.3.4 Asia Pacific Heart Failure POC And LOC Devices Market by Country
    • 7.3.4.1 China Heart Failure POC And LOC Devices Market
      • 7.3.4.1.1 China Heart Failure POC And LOC Devices Market by Test Type
      • 7.3.4.1.2 China Heart Failure POC And LOC Devices Market by End Use
      • 7.3.4.1.3 China Heart Failure POC And LOC Devices Market by Technology
    • 7.3.4.2 Japan Heart Failure POC And LOC Devices Market
      • 7.3.4.2.1 Japan Heart Failure POC And LOC Devices Market by Test Type
      • 7.3.4.2.2 Japan Heart Failure POC And LOC Devices Market by End Use
      • 7.3.4.2.3 Japan Heart Failure POC And LOC Devices Market by Technology
    • 7.3.4.3 India Heart Failure POC And LOC Devices Market
      • 7.3.4.3.1 India Heart Failure POC And LOC Devices Market by Test Type
      • 7.3.4.3.2 India Heart Failure POC And LOC Devices Market by End Use
      • 7.3.4.3.3 India Heart Failure POC And LOC Devices Market by Technology
    • 7.3.4.4 South Korea Heart Failure POC And LOC Devices Market
      • 7.3.4.4.1 South Korea Heart Failure POC And LOC Devices Market by Test Type
      • 7.3.4.4.2 South Korea Heart Failure POC And LOC Devices Market by End Use
      • 7.3.4.4.3 South Korea Heart Failure POC And LOC Devices Market by Technology
    • 7.3.4.5 Singapore Heart Failure POC And LOC Devices Market
      • 7.3.4.5.1 Singapore Heart Failure POC And LOC Devices Market by Test Type
      • 7.3.4.5.2 Singapore Heart Failure POC And LOC Devices Market by End Use
      • 7.3.4.5.3 Singapore Heart Failure POC And LOC Devices Market by Technology
    • 7.3.4.6 Malaysia Heart Failure POC And LOC Devices Market
      • 7.3.4.6.1 Malaysia Heart Failure POC And LOC Devices Market by Test Type
      • 7.3.4.6.2 Malaysia Heart Failure POC And LOC Devices Market by End Use
      • 7.3.4.6.3 Malaysia Heart Failure POC And LOC Devices Market by Technology
    • 7.3.4.7 Rest of Asia Pacific Heart Failure POC And LOC Devices Market
      • 7.3.4.7.1 Rest of Asia Pacific Heart Failure POC And LOC Devices Market by Test Type
      • 7.3.4.7.2 Rest of Asia Pacific Heart Failure POC And LOC Devices Market by End Use
      • 7.3.4.7.3 Rest of Asia Pacific Heart Failure POC And LOC Devices Market by Technology
• 7.4 LAMEA Heart Failure POC And LOC Devices Market
  • 7.4.1 LAMEA Heart Failure POC And LOC Devices Market by Test Type
    • 7.4.1.1 LAMEA Proteomic Testing Market by Country
    • 7.4.1.2 LAMEA Metabolomic Testing Market by Country
    • 7.4.1.3 LAMEA Genomic Testing Market by Country
  • 7.4.2 LAMEA Heart Failure POC And LOC Devices Market by End Use
    • 7.4.2.1 LAMEA Clinics Market by Country
    • 7.4.2.2 LAMEA Hospitals Market by Country
    • 7.4.2.3 LAMEA Laboratory Market by Country
    • 7.4.2.4 LAMEA Assisted Living Healthcare Facilities Market by Country
    • 7.4.2.5 LAMEA Home Market by Country
  • 7.4.3 LAMEA Heart Failure POC And LOC Devices Market by Technology
    • 7.4.3.1 LAMEA Microfluidics Market by Country
    • 7.4.3.2 LAMEA Array-Based Systems Market by Country
    • 7.4.3.3 LAMEA Others Market by Country
  • 7.4.4 LAMEA Heart Failure POC And LOC Devices Market by Country
    • 7.4.4.1 Brazil Heart Failure POC And LOC Devices Market
      • 7.4.4.1.1 Brazil Heart Failure POC And LOC Devices Market by Test Type
      • 7.4.4.1.2 Brazil Heart Failure POC And LOC Devices Market by End Use
      • 7.4.4.1.3 Brazil Heart Failure POC And LOC Devices Market by Technology
    • 7.4.4.2 Argentina Heart Failure POC And LOC Devices Market
      • 7.4.4.2.1 Argentina Heart Failure POC And LOC Devices Market by Test Type
      • 7.4.4.2.2 Argentina Heart Failure POC And LOC Devices Market by End Use
      • 7.4.4.2.3 Argentina Heart Failure POC And LOC Devices Market by Technology
    • 7.4.4.3 UAE Heart Failure POC And LOC Devices Market
      • 7.4.4.3.1 UAE Heart Failure POC And LOC Devices Market by Test Type
      • 7.4.4.3.2 UAE Heart Failure POC And LOC Devices Market by End Use
      • 7.4.4.3.3 UAE Heart Failure POC And LOC Devices Market by Technology
    • 7.4.4.4 Saudi Arabia Heart Failure POC And LOC Devices Market
      • 7.4.4.4.1 Saudi Arabia Heart Failure POC And LOC Devices Market by Test Type
      • 7.4.4.4.2 Saudi Arabia Heart Failure POC And LOC Devices Market by End Use
      • 7.4.4.4.3 Saudi Arabia Heart Failure POC And LOC Devices Market by Technology
    • 7.4.4.5 South Africa Heart Failure POC And LOC Devices Market
      • 7.4.4.5.1 South Africa Heart Failure POC And LOC Devices Market by Test Type
      • 7.4.4.5.2 South Africa Heart Failure POC And LOC Devices Market by End Use
      • 7.4.4.5.3 South Africa Heart Failure POC And LOC Devices Market by Technology
    • 7.4.4.6 Nigeria Heart Failure POC And LOC Devices Market
      • 7.4.4.6.1 Nigeria Heart Failure POC And LOC Devices Market by Test Type
      • 7.4.4.6.2 Nigeria Heart Failure POC And LOC Devices Market by End Use
      • 7.4.4.6.3 Nigeria Heart Failure POC And LOC Devices Market by Technology
    • 7.4.4.7 Rest of LAMEA Heart Failure POC And LOC Devices Market
      • 7.4.4.7.1 Rest of LAMEA Heart Failure POC And LOC Devices Market by Test Type
      • 7.4.4.7.2 Rest of LAMEA Heart Failure POC And LOC Devices Market by End Use
      • 7.4.4.7.3 Rest of LAMEA Heart Failure POC And LOC Devices Market by Technology

Chapter 8. Company Profiles

• 8.1 Abbott Laboratories
  • 8.1.1 Company Overview
  • 8.1.2 Financial Analysis
  • 8.1.3 Segmental and Regional Analysis
  • 8.1.4 Research & Development Expense
  • 8.1.5 Recent strategies and developments:
    • 8.1.5.1 Acquisition and Mergers:
  • 8.1.6 SWOT Analysis
• 8.2 Siemens Healthineers AG (Siemens AG)
  • 8.2.1 Company Overview
  • 8.2.2 Financial Analysis
  • 8.2.3 Segmental and Regional Analysis
  • 8.2.4 Research & Development Expense
  • 8.2.5 Recent strategies and developments:
    • 8.2.5.1 Product Launches and Product Expansions:
  • 8.2.6 SWOT Analysis
• 8.3 Danaher Corporation
  • 8.3.1 Company Overview
  • 8.3.2 Financial Analysis
  • 8.3.3 Segmental and Regional Analysis
  • 8.3.4 Research & Development Expense
  • 8.3.5 SWOT Analysis
• 8.4 F. Hoffmann-La Roche Ltd.
  • 8.4.1 Company Overview
  • 8.4.2 Financial Analysis
  • 8.4.3 Segmental and Regional Analysis
  • 8.4.4 Research & Development Expense
  • 8.4.5 Recent strategies and developments:
    • 8.4.5.1 Partnerships, Collaborations, and Agreements:
  • 8.4.6 SWOT Analysis
• 8.5 BioMerieux S.A.
  • 8.5.1 Company Overview
  • 8.5.2 Financial Analysis
  • 8.5.3 Segmental and Regional Analysis
  • 8.5.4 Research & Development Expenses
  • 8.5.5 Recent strategies and developments:
    • 8.5.5.1 Partnerships, Collaborations, and Agreements:
  • 8.5.6 SWOT Analysis
• 8.6 QuidelOrtho Corporation
  • 8.6.1 Company Overview
  • 8.6.2 Financial Analysis
  • 8.6.3 Regional Analysis
  • 8.6.4 Research & Development Expense
• 8.7 Trinity Biotech plc
  • 8.7.1 Company Overview
  • 8.7.2 Financial Analysis
  • 8.7.3 Regional Analysis
  • 8.7.4 Research & Development Expenses
  • 8.7.5 SWOT Analysis
• 8.8 Jant Pharmacal Corporation
  • 8.8.1 Company Overview
• 8.9 Abaxis, Inc. (Zoetis Services LLC)
  • 8.9.1 Company Overview
  • 8.9.2 Financial Analysis
  • 8.9.3 Regional Analysis
  • 8.9.4 Research & Development Expenses
• 8.10. Werfen, S.A.
  • 8.10.1 Company Overview
  • 8.10.2 SWOT Analysis

Chapter 9. Winning Imperatives of Heart Failure POC And LOC Devices Market